NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL), a leader in the development and commercialization of novel cancer therapeutics, today announced that it has received approval from the Food and Drug Administration for a second facility to manufacture ERBITUX®. The approval to manufacture ERBITUX in this new 250,000-square-foot multi-suite manufacturing facility, referred to as “BB50”, more than doubles ImClone’s total available production volume capacity for ERBITUX. This approval, in conjunction with ImClone’s existing “BB36” manufacturing facility, enhances the Company’s ability to meet increasing demand for ERBITUX in the worldwide market.
